VRTX $235.83 0.33 (0.1%)

    VRTX Profile

    VRTX trades on the NASDAQ.

    MEMBERSHIP
    Nasdaq 100 S&P 500




    Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.

    VRTX Earnings


    Q2 Earnings for Apr, May & Jun

    Wed, Jul 31, 2019

    Since Earnings Report

    VRTX +39.1%


    Q3 Earnings for Jul, Aug & Sep

    Wed, Oct 30, 2019

    Since Earnings Report

    VRTX +19.2%

    VRTX Dividend

    Dividend Yield

    0.00%

    Dividend Rate

    $0.00



    Dividend Pay Date

    --



    Dividend Payments

    --


    VRTX Industry Competitors


    BIOTECH & PHARMA
    Johnson & Johnson
    Merck
    Pfizer
    Bristol-Myers Squibb
    Novo Nordisk A/S
    Amgen
    Eli Lilly
    AbbVie
    Sanofi SA (ADR)
    Gilead Sciences

    BIOTECH & PHARMA



    Symbol MC DY Price Day YTD
    VRTX $60.21 0.00% $235.83 0.1% 7.5%






        TOP    




    info@symbolsurfing.com


    Stock Market Terms

    Remove Blur With Premium Subscription

    Symbol Surfing

    ©2020 Symbol Surfing All Rights Reserved.

    Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

    Cookies Policy Terms Of Service Privacy Policy